Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.
about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin combination therapy for vivax malariaThe effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient dataGametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient dataAn open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaEfficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesEfficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trialImpact of Schistosoma mansoni on malaria transmission in Sub-Saharan AfricaPopulation Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.Malaria in Dielmo, a Senegal village: Is its elimination possible after seven years of implementation of long-lasting insecticide-treated nets?Plasmodium falciparum gametocyte carriage is associated with subsequent Plasmodium vivax relapse after treatment.A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmissionApplication of mobile-technology for disease and treatment monitoring of malaria in the "Better Border Healthcare Programme"Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in ThailandArtemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenIncreased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationRandomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT intervalA phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial.Artemisinin Antimalarials: Preserving the "Magic Bullet"Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola.Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies.Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsOrally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover studyMonitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance.Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical AssessmentPopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarialsThe efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.
P2860
Q21032449-AB6001F0-DB99-469D-9416-F07951AA2A13Q24202910-E5F7CBE1-DA27-491B-80A7-EF6AB6259803Q24235351-E4D67881-5112-4C2C-967E-79CFDE303C2CQ24622539-DFEB20FA-A1C2-443F-98B8-6D7E0DBCCF47Q26822489-86C5CB8D-6794-4993-823C-151BDE6C034DQ28068072-82097CE1-3572-4E5C-AD77-6A2EC3F8CAB6Q28474978-0A34611E-D2B0-4490-9751-973023099AEAQ28535686-0B702ED8-CCC4-451E-B7EA-400F5A4647ADQ28541521-28D23AF3-9F44-4AE9-8728-1416509A212AQ28543825-90534E08-A460-4123-9D73-2B63036AEF18Q31153944-46CBC254-8F16-4FA4-A4AF-BA9F0FCE0CF6Q33622892-E2FE1DC4-9E00-47FC-BC20-6DB9646008C9Q33678483-1C29260E-ACFF-4723-8E52-9B2C3A3D8743Q33772980-46E38876-6219-418E-B4DC-1199DCA5AE82Q33873843-5B4DA0EC-F7E4-4F86-9CCC-A69BDFE4CA5BQ33886228-24C181D3-711A-480E-980A-2DF48D13E088Q34020818-3CA1A21E-F5AC-4902-8CEC-9197A5AD29F0Q34114580-03D39D75-42EC-45B3-B07E-84ABF2228528Q34116219-D99F7B5B-82CC-4CF8-8E80-66834F3F5605Q34137766-8F5C6F12-E077-4773-8D32-DFED45F30E53Q34160147-433E4CD5-D3E8-44CC-9428-E4822653FA9BQ34164652-96C0E82E-DBFD-4723-9768-261D4C9B3936Q34177472-6D0B5A6A-F293-4B74-8E81-14D277D466DBQ34298973-F775B842-D71B-4FC5-BA42-672C530F8591Q34341784-B1A88A64-71CD-4945-8926-1F59C91571ABQ34486508-FCECE31C-659A-4306-AFB0-50C9B5F4B3B5Q34622342-3EEF13E7-E19A-4D13-8748-97D575E84A30Q34922694-8E4CA3E3-4C99-4001-A214-AFAB1F9612B0Q35004430-36020A0A-BE66-4F25-864E-780B678E52D1Q35055212-53919167-29FD-44B7-A504-CCFD93613AD3Q35056250-16C9D8D1-3339-43B9-80CC-90BB0FBF474AQ35071899-6676B7B1-F9B5-41C6-B6E8-EFD855C8208CQ35598379-3D3F3193-C137-49AA-95B1-4DC35E2787CCQ35746240-F776498F-B0C4-42BF-9BD6-26F90324F2F0Q35806356-DDBE22AD-C72E-4F22-A070-93EC50D77BB7Q35859839-7188180C-962D-405F-8506-554C331C5C76Q35867343-767E7B5A-B035-4E47-B861-B26175A0B4A6Q36018642-9152372A-04F3-46B3-9EE0-52BE2EEF58A8Q36018689-3ED8F5BC-0B05-476F-9DB8-5378461145B3Q36138872-08843208-10E9-4472-BC19-2C2BD849AAFC
P2860
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and efficacy of dihydro ...... ividual patient data analysis.
@ast
Safety and efficacy of dihydro ...... ividual patient data analysis.
@en
type
label
Safety and efficacy of dihydro ...... ividual patient data analysis.
@ast
Safety and efficacy of dihydro ...... ividual patient data analysis.
@en
prefLabel
Safety and efficacy of dihydro ...... ividual patient data analysis.
@ast
Safety and efficacy of dihydro ...... ividual patient data analysis.
@en
P2093
P2860
P50
P921
P1433
P1476
Safety and efficacy of dihydro ...... ividual patient data analysis.
@en
P2093
Bart Janssens
Elizabeth A Ashley
Frank Smithuis
Paul Newton
P2860
P356
10.1371/JOURNAL.PONE.0006358
P407
P50
P577
2009-07-29T00:00:00Z